Amgen Czech Republic

Profit Statement 2015 2016 2017
Sales CZK mil 604 626 417
Gross Profit CZK mil 159 152 162
EBITDA CZK mil 46.3 38.8 49.0
EBIT CZK mil 44.3 38.1 48.5
Financing Cost CZK mil 0.330 0.142 0.335
Pre-Tax Profit CZK mil 44.0 38.0 48.2
Net Profit CZK mil 35.8 31.5 37.8
Dividends CZK mil 0 60.0 ...
Balance Sheet 2015 2016 2017
Total Assets CZK mil 276 293 261
Non-Current Assets CZK mil 1.43 1.12 0.726
Current Assets CZK mil 274 291 260
Working Capital CZK mil 67.4 282 248
Shareholders' Equity CZK mil 183 214 192
Liabilities CZK mil 93.3 78.5 68.6
Total Debt CZK mil 71.8 0 0
Net Debt CZK mil 70.7 -0.269 -0.283
Ratios 2015 2016 2017
ROE % 18.4 15.9 18.6
ROCE % 36.6 17.9 14.2
Gross Margin % 26.3 24.2 38.8
EBITDA Margin % 7.66 6.20 11.8
EBIT Margin % 7.34 6.09 11.6
Net Margin % 5.93 5.03 9.06
Net Debt/EBITDA 1.53 -0.007 -0.006
Net Debt/Equity % 38.7 -0.125 -0.147
Cost of Financing % 0.592 0.396 ...
Cash Flow 2015 2016 2017
Total Cash From Operations CZK mil 130 -13.1 118
Total Cash From Investing CZK mil -69.9 12.4 -58.4
Total Cash From Financing CZK mil -60.0 0 -60.0
Net Change In Cash CZK mil -0.159 -0.749 0.014
Cash Conversion Cycle days 37.6 163 211
Cash Earnings CZK mil 37.8 32.2 38.3
Free Cash Flow CZK mil 59.8 -0.749 60.0

Get all company financials in excel:

Download Sample   $19.99

summary Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                            
Sales CZK mil ...             422 416 468 637 604    
Gross Profit CZK mil ...             177 154 159 169 159    
EBIT CZK mil ...             56.3 35.0 38.9 52.5 44.3    
Net Profit CZK mil ...             46.2 28.3 28.7 40.5 35.8    
ROE % ...             31.6 15.4 15.8 21.7 18.4    
EBIT Margin % ...             13.3 8.40 8.32 8.25 7.34    
Net Margin % ...             10.9 6.81 6.14 6.36 5.93    
Employees               72.0 66.0 67.0 65.0 65.0    
balance sheet                            
Total Assets CZK mil ...             227 259 218 267 276    
Non-Current Assets CZK mil ...             6.77 5.13 4.91 2.67 1.43    
Current Assets CZK mil ...             219 253 213 263 274    
Shareholders' Equity CZK mil ...             169 198 167 207 183    
Liabilities CZK mil ...             57.1 60.8 51.9 60.3 93.3    
Non-Current Liabilities CZK mil ...             0.029 0.029 0.029 0 0    
Current Liabilities CZK mil ...             55.7 59.2 51.8 59.7 92.9    
Net Debt/EBITDA ...             0 0 -0.005 0.709 1.53    
Net Debt/Equity % ...             0 0 -0.133 18.6 38.7    
Cost of Financing % ... ... ... ... ... ... ... ... ... 1,890 11.3 0.592   ...
cash flow                            
Total Cash From Operations CZK mil ... ...           52.0 20.0 81.2 -43.7 130    
Total Cash From Investing CZK mil ... ...           -52.0 -20.0 -21.0 44.7 -69.9    
Total Cash From Financing CZK mil ... ...           0 0 -60.0 -0.028 -60.0    
Net Change In Cash CZK mil ... ...           0 0 0.251 0.926 -0.159    
income statement Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                            
Sales CZK mil ...             422 416 468 637 604    
Cost of Goods & Services CZK mil ...             245 262 309 467 445    
Gross Profit CZK mil ...             177 154 159 169 159    
Staff Cost CZK mil ...             111 106 102 98.2 96.4    
Other Cost CZK mil ...             7.27 11.1 15.8 16.7 16.4    
EBITDA CZK mil ...             58.3 37.3 41.1 54.4 46.3    
Depreciation CZK mil ...             2.02 2.31 2.21 1.94 1.93    
EBIT CZK mil ...             56.3 35.0 38.9 52.5 44.3    
Financing Cost CZK mil ...             -0.196 -0.315 0.274 2.25 0.330    
Extraordinary Cost CZK mil ...             0 0 0 0 0    
Pre-Tax Profit CZK mil ...             56.5 35.3 38.6 50.2 44.0    
Tax CZK mil ...             10.3 6.94 7.90 9.76 8.17    
Minorities CZK mil ...             0 0 0 0 0    
Net Profit CZK mil ...             46.2 28.3 28.7 40.5 35.8    
Dividends CZK mil ... ... ... ... ... ... ... ... ... ... ... 0   ...
growth rates                            
Total Revenue Growth % ... ...           17.8 -1.40 12.4 36.0 -5.06    
Operating Cost Growth % ... ...           8.84 -1.44 0.493 -2.18 -1.76    
EBITDA Growth % ... ...           50.4 -36.1 10.4 32.3 -15.0    
EBIT Growth % ... ...           56.9 -37.9 11.3 34.9 -15.5    
Pre-Tax Profit Growth % ... ...           55.9 -37.5 9.53 30.0 -12.4    
Net Profit Growth % ... ...           57.1 -38.7 1.42 40.8 -11.4    
ratios                            
ROE % ...             31.6 15.4 15.8 21.7 18.4    
ROCE % ... ...           48.3 26.3 33.8 44.9 36.6    
Gross Margin % ...             41.9 37.0 33.9 26.6 26.3    
EBITDA Margin % ...             13.8 8.95 8.79 8.55 7.66    
EBIT Margin % ...             13.3 8.40 8.32 8.25 7.34    
Net Margin % ...             10.9 6.81 6.14 6.36 5.93    
Payout Ratio % ... ... ... ... ... ... ... ... ... ... ... 0   ...
Cost of Financing % ... ... ... ... ... ... ... ... ... 1,890 11.3 0.592   ...
Net Debt/EBITDA ...             0 0 -0.005 0.709 1.53    
balance sheet Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
balance sheet                            
Non-Current Assets CZK mil ...             6.77 5.13 4.91 2.67 1.43    
Property, Plant & Equipment CZK mil ...             5.47 3.81 2.82 2.67 1.43    
Intangible Assets CZK mil ...             1.29 1.32 1.25 1.81 1.35    
Goodwill CZK mil ... ... ... ... ... ... ... ... ... ... 0.857 0.081    
Current Assets CZK mil ...             219 253 213 263 274    
Inventories CZK mil ...             0 0 0 0 0    
Receivables CZK mil ...             99.5 112 48.4 137 81.9    
Cash & Cash Equivalents CZK mil ...             0 0 0.251 1.18 1.02    
Total Assets CZK mil ...             227 259 218 267 276    
Shareholders' Equity CZK mil ...             169 198 167 207 183    
Of Which Minority Interest CZK mil ...             0 0 0 0 0    
Liabilities CZK mil ...             57.1 60.8 51.9 60.3 93.3    
Non-Current Liabilities CZK mil ...             0.029 0.029 0.029 0 0    
Long-Term Debt CZK mil ...             0 0 0.029 0 0    
Deferred Tax Liabilities CZK mil ...             0 0 0 0 0    
Current Liabilities CZK mil ...             55.7 59.2 51.8 59.7 92.9    
Short-Term Debt CZK mil ...             0 0 0 39.8 71.8    
Trade Payables CZK mil ...             7.08 0.645 0.029 12.6 14.4    
Provisions CZK mil ...             1.27 1.54 0 0 0    
Equity And Liabilities CZK mil ...             227 259 218 267 276    
growth rates                            
Total Asset Growth % ... ...           36.5 14.1 -15.6 22.4 3.28    
Shareholders' Equity Growth % ... ...           37.5 16.7 -15.8 24.3 -11.7    
Net Debt Growth % ... ...           ... ... ... -17,482 83.3    
Total Debt Growth % ... ... ... ... ... ... ... ... ... ... 137,021 80.5   ...
ratios                            
Total Debt CZK mil ...             0 0 0.029 39.8 71.8    
Net Debt CZK mil ...             0 0 -0.222 38.6 70.7    
Working Capital CZK mil ...             92.4 111 48.4 124 67.4    
Capital Employed CZK mil ...             99.2 117 53.3 127 68.9    
Net Debt/Equity % ...             0 0 -0.133 18.6 38.7    
Cost of Financing % ... ... ... ... ... ... ... ... ... 1,890 11.3 0.592   ...
cash flow Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
cash flow                            
Net Profit CZK mil ...             46.2 28.3 28.7 40.5 35.8    
Depreciation CZK mil ...             2.02 2.31 2.21 1.94 1.93    
Non-Cash Items CZK mil ... ...           11.5 8.40 -12.8 -10.3 35.2    
Change in Working Capital CZK mil ... ...           -7.70 -19.0 63.1 -75.8 56.8    
Total Cash From Operations CZK mil ... ...           52.0 20.0 81.2 -43.7 130    
Capital Expenditures CZK mil ... ...           -2.00 -1.00 -1.15 -0.543 -0.695    
Other Investments CZK mil ... ...           -50.0 -19.0 -19.8 45.2 -69.3    
Total Cash From Investing CZK mil ... ...           -52.0 -20.0 -21.0 44.7 -69.9    
Dividends Paid CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
Issuance Of Shares CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
Issuance Of Debt CZK mil ... ...           0 0 0.029 39.7 32.0    
Total Cash From Financing CZK mil ... ...           0 0 -60.0 -0.028 -60.0    
Net Change In Cash CZK mil ... ...           0 0 0.251 0.926 -0.159    
ratios                            
Days Sales Outstanding days ...             86.0 98.3 37.8 78.4 49.5    
Days Sales Of Inventory days ...             0 0 0 0 0    
Days Payable Outstanding days ...             10.5 0.898 0.034 9.84 11.8    
Cash Conversion Cycle days ...             75.5 97.4 37.7 68.6 37.6    
Cash Earnings CZK mil ...             48.2 30.6 31.0 42.4 37.8    
Free Cash Flow CZK mil ... ...           0 0 60.3 0.954 59.8    
other data Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
other data                            
ROA % ...             23.5 11.7 12.0 16.7 13.2    
Gross Margin % ...             41.9 37.0 33.9 26.6 26.3    
Employees               72.0 66.0 67.0 65.0 65.0    
Cost Per Employee USD per month ...             7,282 6,827 6,457 5,890 5,178    
Cost Per Employee (Local Currency) CZK per month ...             128,795 133,538 126,332 125,883 123,604    
Staff Cost (As % Of Total Cost) % ...             30.4 27.7 23.7 16.8 17.2    
Effective Tax Rate % ...             18.2 19.7 20.4 19.4 18.6    
Sales From Agency Activity CZK mil ...             190 184 176 176 166    
Sales From Services For Clinical Studies CZK mil ...             233 232 292 460 438    
Capital Expenditures (As % of Sales) % ... ...           0.474 0.240 0.245 0.085 0.115    

Get all company financials in excel:

Download Sample   $19.99

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases

Amgen Czech Republic Logo